Champions Oncology(CSBR) - 2026 Q2 - Quarterly Results

Financial Performance - Total revenue for the second quarter of fiscal 2026 was $15.0 million, an increase of 11.5% compared to $13.5 million in the same period last year[5] - Net income for the second quarter was $237,000, compared to $728,000 in the same quarter of the previous year[6] - Total revenue for the first half of fiscal 2026 was $29.0 million, a 5.4% increase from $27.6 million in the prior year[11] - Oncology revenue for the three months ended October 31, 2025, was $15.035 million, an increase from $13.489 million in the same period of 2024, representing a growth of 11.5%[27] - Net income attributable to the company's common shares for the three months ended October 31, 2025, was $268,000, compared to $728,000 in the same period of 2024, a decrease of 63.2%[27] Profitability Metrics - Oncology services profit was $7.8 million with a margin of 52%, up from 45% in the same quarter of the previous year[7] - Adjusted EPS - diluted, Non-GAAP for the three months ended October 31, 2025, was $0.06, compared to $0.08 in the same period of 2024, reflecting a decrease of 25%[26] - Oncology services margin for the first half of fiscal 2026 was 47%, consistent with the prior year[13] - The oncology services margin - Non-GAAP for the three months ended October 31, 2025, was 52%, compared to 45% in the same period of 2024[26] Expenses - Adjusted EBITDA for the second quarter was $843,000, down from $1.1 million in the same quarter of fiscal 2025[6] - Research and development expenses for the second quarter increased by 54.9% to $2.6 million, reflecting greater investment in the data licensing platform[8] - Operating expenses for the second quarter rose by 16.4% to $14.9 million, driven by targeted investments in growth areas[5] - Income from operations for the six months ended October 31, 2025, was a loss of $342,000, compared to a profit of $2.061 million in the same period of 2024[27] - Research and development expenses for the six months ended October 31, 2025, were $4.698 million, up from $3.143 million in the same period of 2024, indicating a 49.4% increase[27] Cash and Assets - The company ended the quarter with approximately $8.5 million in cash and no debt[10] - Cash and cash equivalents as of October 31, 2025, were $8.516 million, a decrease from $9.785 million at the end of the previous reporting period[28] - Total assets as of October 31, 2025, were $30.162 million, down from $32.344 million as of April 30, 2025[28] - Total liabilities as of October 31, 2025, were $25.931 million, down from $28.572 million as of April 30, 2025[28] Market Outlook - The company remains optimistic about the strengthening pharma and biotech funding environment, which is expected to support improved bookings[2] - Net cash used in operating activities for the six months ended October 31, 2025, was $(1.135) million, compared to $28,000 in the same period of 2024[29]